Andrew Huberman, researcher in the Stanford University Department of Neurobiology, is taking an unusual approach to investigating possible treatments for glaucoma and anxiety disorders—virtual reality. https://www.biospace.com/article/virtual-reality-a-potential-new-tool-in-healthcare-and-therapy-r-and-d/
However, it is clear that the pharmaceutical industry is going to continue to invest in R&D at a pretty healthy rate for the foreseeable future. https://www.forbes.com/sites/johnlamattina/2018/06/12/pharma-rd-investments-moderating-but-still-high/
The R&D playbook is evolving as the industry looks to break down the silos between clinical and commercial operations â bringing commercial voices to the earliest phases of asset development. https://www.outsourcing-pharma.com/Article/2018/03/13/Commercial-Trends-Forecast-R-D-is-transforming-into-R-D-C
Clinical Informatics News Contributed Commentary In January 2017, there were 4,003 pharmaceutical companies with nearly 15,000 drugs in the pipeline. Yet only 1 in 5 drugs actually make it to market. Technology inherently aims to streamline processes, eliminate manual effort and create efficiencies, but is technology still doing this for clinical research?
Novartis says it will scale up the use of Apple ResearchKit in clinical trials, as part of its efforts to bring about digital transformation.
The post Novartis and Apple to scale up clinical trial collaboration appeared first on Pharmaphorum. https://pharmaphorum.com/news/researchkit-novartis-apple-scale-clinical-trial-collaboration/
The rise of wearable technology for clinical trials
The post The rise of wearable technology for clinical trials: insights from Novartis appeared first on Pharmaphorum. https://pharmaphorum.com/partner-content/the-rise-of-wearable-technology-for-clinical-trials-insights-from-novartis/
NewsThe Propeller platform has been used by patients and physicians in over 55 commercial programs across the United States.Contributed Author: Propeller HealthTopics: Biotech https://www.dddmag.com/news/2017/08/propeller-health-expands-digital-health-r-d-partnership-gsk
Takeda is increasing its R&D investment in oncology with a collaboration with Texas biotech Molecular Templates. The Japanese
The post Takeda begins new R&D link-up with Molecular Templates appeared first on Pharmaphorum. https://pharmaphorum.com/news/takeda-begins-new-rd-link-molecular-templates/
Adimab, LLC is transferring its proprietary antibody discovery and optimization platform to Lilly research sites in San Diego and New York. http://www.outsourcing-pharma.com/Preclinical-Research/Eli-Lilly-licenses-Adimab-antibody-discovery-and-optimization-tech